| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Andrew Booth is Chief Financial Officer at ABCL. Andrew Booth's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.9M at current prices.
Our model assigns Andrew Booth a below-average insider score of 47/100, based on 5 past trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -0.7%.
The ABCL filings lean toward selling, a net 953,200 shares.
Andrew Booth has 15 Form 4 filings on record from June 2021 to August 2026, all as Chief Financial Officer at AbCellera Biologics (ABCL), 2021–2026.
The 18 reported transactions were 6 open-market purchases, 5 option exercises, 5 option or other derivative awards and 1 gift, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 5 purchases worth about $2.1M and 1 sale worth about $30.6M.
The largest open-market purchase was 67,500 shares of ABCL at an average $14.71 on November 11, 2021, about $993K. Twelve months later ABCL was down 10%.
The only open-market sale was 1,200,000 shares of ABCL at an average $25.50 on June 9, 2021, about $30.6M. Twelve months later ABCL was down 65%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | ABCL Abcellera Biologics Inc. | Chief Financial Officer | Buy | 37,200 | $10.32 | $383,904.00 | +8.3% | - | - | |
| Feb 27, 2026 | ABCL Abcellera Biologics Inc. | Chief Financial Officer | Buy | 42,600 | $3.42 | $145,692.00 | +27.8% | +59.2% | - | |
| May 26, 2023 | ABCL Abcellera Biologics Inc. | Chief Financial Officer | Buy | 14,500 | $6.85 | $99,325.00 | +10.5% | -19.1% | -43.4% | |
| May 12, 2022 | ABCL Abcellera Biologics Inc. | Chief Financial Officer | Buy | 85,000 | $5.79 | $492,150.00 | +158.9% | +98.8% | -14.5% | |
| Nov 11, 2021 | ABCL Abcellera Biologics Inc. | Chief Financial Officer | Buy | 67,500 | $14.71 | $993,130.00 | +106.4% | -35.7% | -9.8% | |
| Jun 9, 2021 | ABCL Abcellera Biologics Inc. | Chief Financial Officer | Sell | 1,200,000 | $25.50 | $30,600,000.00 | -100% | -20.5% | -64.8% |